Erschienen in:
01.11.2018 | Orphan Diseases (Bernhard Manger, Section Editor)
Hypophosphatasia: From Diagnosis to Treatment
verfasst von:
Sebastian Simon, Heinrich Resch, Klaus Klaushofer, Paul Roschger, Jochen Zwerina, Roland Kocijan
Erschienen in:
Current Rheumatology Reports
|
Ausgabe 11/2018
Einloggen, um Zugang zu erhalten
Abstract
Purpose of Review
Hypophosphatasia (HPP) is a rare genetic disorder caused by mutations of the ALPL gene. ALPL encodes the tissue-non-specific isoenzyme of alkaline phosphatase (TNSALP). Consequently, bone mineralization is decreased leading to fractures, arthralgia, and extra-skeletal manifestations including tissue calcification, respiratory failure, and neurological complications. This review summarizes the most important clinical findings, diagnosis, and treatment options for HPP.
Recent Findings
Asfotase alfa is a recombinant human alkaline phosphatase, used as treatment for the underlying cause of HPP. Asfotase alfa enhances the survival in life-threatening HPP and improves bone mineralization, muscle strength, and pulmonary function. However, discontinuation of asfotase alfa leads to reappearance of bone hypomineralization.
Summary
Due to its varied manifestations, HPP often mimics rheumatological and other bone diseases, thereby delaying its diagnosis. Asfotase alfa, a recombinant alkaline phosphatase, is available for the long-term enzyme replacement therapy in patients with pediatric-onset HPP to treat the bone manifestations of the disease.